Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

← catalyst calendar

NCT05696626 · readout ≤ 254 d

Sponsored by LeonaBio (industry) · LONA — their whole pipeline →.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

600estimated

Sites

224

Countries

Australia, Belgium, Canada +14

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-10-31

actual

When the study began enrolling

Primary completion

Apr 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Apr 2028

estimated

The whole study's end, after follow-up

First posted

2023-01-25

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-22

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Metastatic Breast Cancer

Interventions

Drug: Lasofoxifene in combination with abemaciclib
Drug: Fulvestrant in combination with abemaciclib

Primary outcome

what the primary-completion date above is the date OF

Progression free survival (PFS)

measured Within approximately 3 years

Publications

PMID 40222048 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · LONA's whole pipeline · Catalyst calendar · Every registered study · What changed